Form 4: Avidity Biosciences CEO Sarah Boyce Reports Stock Transactions Following PSU Vesting

Avidity Biosciences CEO Sarah Boyce reports acquisition and disposal of company stock related to the vesting of performance-based restricted stock units (PSUs) and subsequent sell-to-cover transactions.

Summary

• On June 17, 2024, Avidity Biosciences CEO Sarah Boyce acquired 62,500 shares of common stock due to the vesting of performance-based restricted stock units (PSUs) after the company initiated the Phase 3 HARBOR trial for del-desiran.
• These PSUs converted to time-based restricted stock units that will vest on December 17, 2024, contingent upon continued employment.
• To cover tax withholding obligations related to the PSU vesting, Boyce sold 32,074 shares on June 18, 2024, at a weighted-average price of $39.1295 per share.
• The sales were executed as part of a 'sell-to-cover' transaction mandated by the Issuer's equity incentive plans and were not a discretionary trade.
• Following these transactions, Boyce directly owns 142,543 shares of Avidity Biosciences common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The vesting of PSUs indicates progress on a key clinical trial, which is a positive signal. The sale of shares for tax purposes is a neutral event.

Positives

• The vesting of PSUs indicates the achievement of a key company milestone: the initiation of the Phase 3 HARBOR trial for del-desiran.
• The CEO's continued holding of a significant number of shares (142,543) suggests confidence in the company's future prospects.

Negatives

• The sale of shares, even for tax purposes, could be perceived negatively by some investors, although it was a mandated 'sell-to-cover' transaction.

Risks

• The vesting of the remaining time-based restricted stock units is contingent upon the CEO's continued employment, creating a potential risk if she were to leave the company before December 17, 2024.

Future Outlook

The remaining time-based restricted stock units will vest on December 17, 2024, subject to the CEO's continued employment.

Industry Context

This filing is a routine disclosure related to executive compensation and stock ownership. The vesting of PSUs tied to clinical trial milestones is common in the biotechnology industry, aligning executive incentives with company progress.

Comparison to Industry Standards

• Executive compensation packages in the biotechnology industry often include performance-based equity awards tied to clinical trial milestones, similar to the PSUs granted to Sarah Boyce.
• Sell-to-cover transactions are a standard practice for executives to manage tax obligations related to equity compensation.
• Comparing Sarah Boyce's stock ownership to that of CEOs at comparable biotechnology companies would provide further context, but that data is not available in this document.

Stakeholder Impact

• Shareholders may view the vesting of PSUs as a positive sign of company progress.
• Employees may be motivated by the achievement of the clinical trial milestone.
• The 'sell-to-cover' transaction has a minimal impact on other stakeholders.

Next Steps

• The remaining time-based restricted stock units will vest on December 17, 2024, subject to the CEO's continued employment.

Key Dates